MinorOther dermatologicals (topical); peripheral vasodilators (systemic)×Bile acid preparations
Updated · Methodology
Mechanism
Ursodeoxycholic acid is absorbed in the small intestine, conjugated with glycine or taurine in the liver and secreted into bile. Apart from this conjugation and a small bacterial conversion in the gut, it is not metabolised (ursodeoxycholic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, minoxidil is mainly conjugated with glucuronic acid, and minoxidil and its metabolites are excreted in the urine (minoxidil SmPCs, AEMPS). Between 1% and 2% of a dose of scalp foam or solution reaches the circulation (minoxidil scalp foam SmPC, AEMPS). According to its SmPC, ursodeoxycholic acid could in theory affect the absorption of other lipophilic substances. The minoxidil documents do not describe minoxidil as lipophilic, and at least 90% of an oral minoxidil dose is absorbed (ursodeoxycholic acid and minoxidil SmPCs, AEMPS). No document names the pair.
Symptoms
The documents describe no symptoms of this combination. A common adverse effect of ursodeoxycholic acid is pasty stools or diarrhoea (ursodeoxycholic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the US label lists alopecia among its most common adverse reactions (URSO label, US Food and Drug Administration, FDA). Minoxidil on the scalp commonly causes itching, dermatitis, rash, headache and unwanted hair growth outside the scalp (minoxidil scalp foam SmPC, AEMPS). Minoxidil tablets cause salt and water retention, oedema and, in most people, increased body hair (minoxidil tablets SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of ursodeoxycholic acid and minoxidil need no change. No document names the pair (ursodeoxycholic acid SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and URSO label, US Food and Drug Administration, FDA; minoxidil SmPCs, AEMPS, and minoxidil tablets label, FDA). Ursodeoxycholic acid is used, among other indications, for primary biliary cholangitis. During the first 3 months of treatment, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) are checked every 4 weeks, and every 3 months after that (ursodeoxycholic acid SmPCs, AEMPS). If minoxidil is taken by mouth in hepatic impairment, consider whether the dose needs adjusting: start with a reduced dose once daily and increase it gradually to the lowest effective dose (minoxidil tablets SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Minoxidil, Regaine 50 mg/g espuma cutánea (nº registro 76483), sección 4.4 (2025)– AEMPS, CIMA, nº registro 76483 (Regaine 50 mg/g espuma cutánea, JNTL Consumer Health), revisión 09/2025, secciones 4.1, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Minoxidil, Loniten 10 mg comprimidos (nº registro 55636), sección 4.4 (2020)– AEMPS, CIMA, nº registro 55636 (Loniten 10 mg comprimidos, Pfizer), revisión 11/2020, secciones 4.1, 4.2, 4.4, 4.5 y 5.2
- FDA: Minoxidil tablets, Sun Pharmaceutical (minoxidil) prescribing information (2026)– FDA, DailyMed setid 0354a7f5-5917-44dc-9963-411104008cb5 (Sun Pharmaceutical Industries), versión 5, 02/2026, Warnings, Precautions (General, Drug interactions, Unapproved use), Clinical Pharmacology
- AEMPS: Ficha técnica: Ácido ursodesoxicólico, Ursobilane 150, 300 y 500 mg cápsulas (nº registro 65732), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65732 (Ursobilane 300 mg cápsulas, Laboratorio Estedi), ficha técnica de 03/2026, secciones 4.1, 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Ácido ursodesoxicólico, Adisocol 500 mg cápsulas duras (nº registro 89784), sección 4.5 (2025)– AEMPS, CIMA, nº registro 89784 (Adisocol 500 mg cápsulas duras EFG, Glenmark), revisión 10/2025, secciones 4.4, 4.5, 4.8 y 5.2
- FDA: URSO 250 and URSO Forte (ursodiol) prescribing information (2023)– FDA, DailyMed setid e8fc4fc2-fe5c-4cba-b6e0-5ceaf2157a61 (Allergan), versión 19, 01/2023, sections 4, 5, 6 and 7